

ABEONA THERAPEUTICS LAUNCHES AD CAMPAIGN & SURVEY FOR MPSIIIA, MPSIIIB TRIALS

Abeona recently launched a concerted effort to enroll more children into ongoing studies of its one-time gene therapies for MPSIIIA and MPSIIIB. The centerpiece is a Facebook advertising campaign and [eligibility survey](#). The latter is intended to help caregivers determine if their child may be able to participate in one of the studies that are enrolling patients 6 months – 2 years of age. Children over 2 must have a development quotient of 60 or above to qualify. Full enrollment criteria is at [Clinicaltrials.gov: MPSIIIA, MPSIIIB](#).

If the 6-question survey indicates a child may be eligible to enroll, the caregiver has the option of having the information sent to the nearest study site for evaluation by the investigator. The study site then engages the family for more information. Abeona does not have access to any patient information that is shared in this process. Survey results can also be downloaded to share with a physician.

Secondly, to bring more awareness to the studies and make them easier to decipher, Abeona has named them The Transpher A Study and The Transpher B Study. These names acknowledge the gene transfer method used by each therapy and the type of Sanfilippo syndrome they aim to treat.

transpher **A**study™ **transpher** **B**study™

This branding appears in the Facebook ads that feature some photos of brave children who have succumbed to the disease. The families graciously provided Abeona with permission to use the photos in the campaign and on the website housing the survey.



More information about the therapies can be found on the [company's website](#) or by contacting patients@abeonatherapeutics.com.